Helena Tayton-Martin
Founder chez ADAPTIMMUNE THERAPEUTICS PLC
Fortune : 474 102 $ au 31/03/2024
Profil
Helena Katrina Tayton-Martin is the founder.
She founded Avidex Ltd.
in 2008, where she held the title of Chief Operating Officer from 2008 to 2017.
She also founded Adaptimmune Ltd.
in 2008 and currently holds the position of COO, Director & Chief Business Officer.
In 2022, she cos-founded Adaptimmune Therapeutics Plc and currently serves as the Chief Business & Strategy Officer.
Dr. Tayton-Martin's current job is President & Secretary at Adaptimmune LLC.
Her former positions include Independent Director at Trillium Therapeutics ULC from 2017 to 2021 and Principal at Medigene, Inc. She obtained a doctorate degree from the University of Bristol and an MBA from London Business School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 15/01/2024 | 1 800 000 ( 0,32% ) | 474 102 $ | 31/03/2024 |
Postes actifs de Helena Tayton-Martin
| Sociétés | Poste | Début |
|---|---|---|
| ADAPTIMMUNE THERAPEUTICS PLC | Founder | 01/01/2008 |
Adaptimmune Ltd.
 Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom. | Founder | 01/01/2008 |
Adaptimmune LLC
 Adaptimmune LLC Medical/Nursing ServicesHealth Services Part of Adaptimmune Therapeutics Plc, Adaptimmune LLC is a private company that focuses on the use of T cell therapy to treat cancer and infectious disease. The company is based in Philadelphia, PA. | President | - |
Anciens postes connus de Helena Tayton-Martin
| Sociétés | Poste | Fin |
|---|---|---|
| TRILLIUM THERAPEUTICS | Director/Board Member | 17/11/2021 |
Avidex Ltd.
 Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | Founder | 01/01/2017 |
MediGene, Inc.
 MediGene, Inc. Pharmaceuticals: MajorHealth Technology MediGene, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The company was founded by Ram Bhatt and Frank Tufaro and is headquartered in San Diego, CA. | Corporate Officer/Principal | - |
Formation de Helena Tayton-Martin
| University of Bristol | Doctorate Degree |
| London Business School | Masters Business Admin |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ADAPTIMMUNE THERAPEUTICS PLC | Health Technology |
| Entreprise privées | 5 |
|---|---|
Trillium Therapeutics ULC
 Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
MediGene, Inc.
MediGene, Inc. Pharmaceuticals: MajorHealth Technology MediGene, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The company was founded by Ram Bhatt and Frank Tufaro and is headquartered in San Diego, CA. | Health Technology |
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | Health Technology |
Adaptimmune Ltd.
Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom. | Health Services |
Adaptimmune LLC
Adaptimmune LLC Medical/Nursing ServicesHealth Services Part of Adaptimmune Therapeutics Plc, Adaptimmune LLC is a private company that focuses on the use of T cell therapy to treat cancer and infectious disease. The company is based in Philadelphia, PA. | Health Services |
